郭海燕, 杨皓然, 史会连, 刘丽娜, 车军勇. 异甘草酸镁与复方甘草酸苷治疗非酒精性脂肪性肝病的疗效比较[J]. 实用临床医药杂志, 2021, 25(16): 36-39. DOI: 10.7619/jcmp.20211632
引用本文: 郭海燕, 杨皓然, 史会连, 刘丽娜, 车军勇. 异甘草酸镁与复方甘草酸苷治疗非酒精性脂肪性肝病的疗效比较[J]. 实用临床医药杂志, 2021, 25(16): 36-39. DOI: 10.7619/jcmp.20211632
GUO Haiyan, YANG Haoran, SHI Huilian, LIU Lina, CHE Junyong. Magnesium isoglycyrrhizinate versus compound glycyrrhizin in treatment of patients with non-alcoholic fatty liver disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(16): 36-39. DOI: 10.7619/jcmp.20211632
Citation: GUO Haiyan, YANG Haoran, SHI Huilian, LIU Lina, CHE Junyong. Magnesium isoglycyrrhizinate versus compound glycyrrhizin in treatment of patients with non-alcoholic fatty liver disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(16): 36-39. DOI: 10.7619/jcmp.20211632

异甘草酸镁与复方甘草酸苷治疗非酒精性脂肪性肝病的疗效比较

Magnesium isoglycyrrhizinate versus compound glycyrrhizin in treatment of patients with non-alcoholic fatty liver disease

  • 摘要:
      目的  比较异甘草酸镁与复方甘草酸苷治疗非酒精性脂肪性肝病(NAFLD)的疗效和安全性。
      方法  将60例NAFLD患者随机分为对照组和观察组,每组30例。对照组患者接受复方甘草酸苷治疗,观察组患者接受异甘草酸镁治疗,比较2组患者的肝功能指标、血脂指标、镁离子水平、临床症状改善情况、疗效、不良反应发生情况。
      结果  观察组总有效率为96.67%, 高于对照组的80.00%, 差异有统计学意义(P < 0.05)。观察组治疗后谷氨酸-丙酮酸转氨酶、天门冬氨酸转氨酶、总胆固醇及甘油三酯水平低于对照组,差异有统计学意义(P < 0.05)。2组均未发生严重不良反应。
      结论   异甘草酸镁能显著改善NAFLD患者的肝功能及血脂指标,且安全性良好。

     

    Abstract:
      Objective  To compare the efficacy and safety of magnesium isoglycyrrhizinate and compound glycyrrhizin in the treatment of patients with non-alcoholic fatty liver disease (NAFLD).
      Methods   Totally 60 patients with NAFLD were divided into control group and observation group according to therapeutic methods, with 30 cases in each group. Patients in the control group were treated with compound glycyrrhizin, and those in the observation group were treated with magnesium isoglycyrrhizinate. The liver function indexes, blood lipid indexes, magnesium ions level, improvement of clinical symptoms, efficacy and adverse reactions were compared between two groups.
      Results   The total effective rate of the observation group was 96.67%, which was significantly higher than 80.00% of the control group (P < 0.05). The levels of glutamic pyruvate transaminase, aspartate transaminase, total cholesterol and triglyceride after treatment in the observation group were significantly lower than those in the control group (P < 0.05). No severe adverse reactions were observed in both groups.
      Conclusion   Magnesium isoglycyrrhizinate can significantly improve liver function and blood lipid indexes of patients with NAFLD, and its safety is high.

     

/

返回文章
返回